IPH-5201

N/A

Report date: 2022/06/06 15:48:43

Base Information

Drug NameIPH-5201
Drug Alias Nameanti-huCD39 mAbIPH-5201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEctonucleoside triphosphate diphosphohydrolase 1 inhibitors
TargetsEctonucleoside triphosphate diphosphohydrolase 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandHungary +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInsermOrega Biotech
China Registration ClassN/A

Develop Information

Active CompaniesInnate PharmaAstrazeneca PlcMedimmune Llc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A